Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Shattuck Labs, Inc.

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Participation in Upcoming March Conferences
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML)
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Shattuck Labs Announces Participation in Upcoming March Conferences
From Shattuck Labs, Inc.
Via GlobeNewswire
Tickers STTK
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.